AKRO Stock Summary and Trading Ideas (Akero Therapeutics | NASDAQ:AKRO)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics trades on the NASDAQ stock market under the symbol AKRO.

As of November 7, 2024, AKRO stock price declined to $34.87 with 457,716 million shares trading.

AKRO has a beta of 1.69, meaning it tends to be more sensitive to market movements. AKRO has a correlation of 0.12 to the broad based SPY ETF.

AKRO has a market cap of $2.42 billion. This is considered a Mid Cap stock.

In the last 3 years, AKRO traded as high as $58.38 and as low as $7.52.

The top ETF exchange traded funds that AKRO belongs to (by Net Assets): IWM, VTI, XBI, VXF, IWN.

AKRO has outperformed the market in the last year with a price return of +124.0% while the SPY ETF gained +37.9%. AKRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +47.3% and +21.3%, respectively, while the SPY returned +15.2% and +2.8%, respectively.

AKRO support price is $34.15 and resistance is $36.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKRO shares will trade within this expected range on the day.